SAB Biotherapeutics (NASDAQ:SABS) Receives “Sell (E+)” Rating from Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research note published on Tuesday morning,Weiss Ratings reports.

Other equities analysts also recently issued research reports about the company. HC Wainwright lowered their price target on SAB Biotherapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. Wall Street Zen upgraded SAB Biotherapeutics to a “sell” rating in a report on Saturday, September 20th. Chardan Capital reiterated a “buy” rating and set a $12.00 price target on shares of SAB Biotherapeutics in a report on Friday, September 19th. Leerink Partners started coverage on SAB Biotherapeutics in a report on Wednesday, September 17th. They set an “outperform” rating and a $7.00 price target on the stock. Finally, Leerink Partnrs upgraded SAB Biotherapeutics to a “strong-buy” rating in a report on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, SAB Biotherapeutics has an average rating of “Moderate Buy” and an average price target of $9.33.

SAB Biotherapeutics Price Performance

Shares of SABS opened at $2.30 on Tuesday. The firm has a market cap of $23.95 million, a PE ratio of -0.58 and a beta of 0.54. The firm’s 50 day moving average price is $2.19 and its 200 day moving average price is $1.96. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.87 and a current ratio of 0.87. SAB Biotherapeutics has a twelve month low of $1.00 and a twelve month high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.27). As a group, research analysts expect that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in SAB Biotherapeutics stock. HB Wealth Management LLC increased its position in SAB Biotherapeutics, Inc. (NASDAQ:SABS) by 10.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 263,200 shares of the company’s stock after purchasing an additional 25,800 shares during the quarter. HB Wealth Management LLC owned approximately 2.83% of SAB Biotherapeutics worth $358,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.